Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting
MWN-AI** Summary
Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company specializing in precision therapies for genetically defined diseases, has announced multiple poster presentations at the upcoming 2026 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia, running from February 27 to March 2, 2026. The posters will showcase significant results from the SUMMIT pivotal trial, which investigated the efficacy of bezuclastinib in patients with NonAdvanced Systemic Mastocytosis (NonAdvSM).
Following the submission of a New Drug Application (NDA) for bezuclastinib to the U.S. Food and Drug Administration (FDA) in December 2025, Cogent is anticipating heightened interest in the trial’s findings, especially given the drug’s Breakthrough Therapy Designation for this patient population. The company aims to highlight various facets of the trial, with presentations scheduled for February 28, 2026.
Key posters include expanded results from the Phase 2 SUMMIT trial, evaluations of bone formation markers, and assessments of patient experiences living with NonAdvSM. Additionally, presentations will cover improvements in symptom burden and the correlation of symptom improvement with objective disease measures, as well as analyses focused on subgroups with unmet needs.
Bezuclastinib itself is a selective tyrosine kinase inhibitor targeting the KIT D816V mutation, a primary driver of systemic mastocytosis. With this drug, Cogent hopes to provide a new therapeutic avenue for patients battling NonAdvSM and other related conditions.
Cogent Biosciences remains committed to advancing its clinical programs while developing a range of innovative treatments targeting genetic mutations associated with severe diseases. For more details, follow Cogent on social media and visit their website.
MWN-AI** Analysis
Cogent Biosciences, Inc. (Nasdaq: COGT) is on the verge of making significant strides in the biotech sector, particularly with its promising candidate, bezuclastinib. Their recent announcement regarding multiple poster presentations at the 2026 AAAAI Annual Meeting provides investors with a critical window of opportunity.
The presentations highlighting results from the SUMMIT trial in patients with Nonadvanced Systemic Mastocytosis (NonAdvSM) come at a pivotal moment, especially following the recent submission of a New Drug Application (NDA) for bezuclastinib to the FDA. The data from the SUMMIT trial have generated a favorable narrative, especially given the Breakthrough Therapy Designation received for the drug. This breakthrough status signifies a strong potential for bezuclastinib to address unmet medical needs, particularly in patients with the KIT D816V mutation, a prevalent factor in systemic mastocytosis.
Investors should closely monitor the outcomes of these presentations, scheduled for February 28, which may influence market sentiment and stock performance. A robust showing could catalyze a bullish trend in the stock price, whereas mixed results may lead to volatility. The detailed analyses on symptom burden and patient experience from the trial can further enhance the investment thesis surrounding Cogent's strategic developments.
Given Cogent’s focus on precision therapies and the strength of its clinical pipeline, this could be an opportune moment to evaluate positions in COGT. Investors might consider gradual accumulation, particularly ahead of major announcements or data releases, preparing for potential volatility but also significant upside as FDA approval becomes more likely. Overall, keeping a keen eye on developments at the AAAAI meeting will be crucial for gauging the company’s trajectory in the competitive biotech landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
WALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced multiple upcoming posters highlighting bezuclastinib results from the SUMMIT trial in NonAdvanced Systemic Mastocytosis (NonAdvSM) patients at the 2026 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI) being held in Philadelphia, PA, February 27-March 2, 2026.
In December 2025, Cogent announced that the company submitted its New Drug Application for bezuclastinib in NonAdvSM to the U.S. Food and Drug Administration. The submission is based on positive clinical data from the SUMMIT pivotal trial and follows the Breakthrough Therapy Designation for bezuclastinib in patients with SSM and patients with NonAdvSM who have received prior avapritinib.
AAAAI Poster Details:
Poster Presentation Title: Expanded Results from the Phase 2 Summit Trial: Bezuclastinib in Adults with Nonadvanced Systemic Mastocytosis
Session Date and Time: February 28, 2026 – 9:45am – 10:45am ET
Poster Number: 519
Location: Convention Center, Ground Level, Hall A
Poster Presentation Title: Evaluation of Bone Formation Marker Changes in Summit, a Trial Assessing Bezuclastinib in Adults with Nonadvanced Systemic Mastocytosis: An Exploratory Analysis
Session Date and Time: February 28, 2026 – 9:45am – 10:45am ET
Poster Number: 520
Location: Convention Center, Ground Level, Hall A
Poster Presentation Title: Results From the Phase 2 Summit Trial of Bezuclastinib in Adults with Nonadvanced Systemic Mastocytosis: Patient Experience of Living with NonAdvSM
Session Date and Time: February 28, 2026 – 9:45am – 10:45am ET
Poster Number: 510
Location: Convention Center, Ground Level, Hall A
Poster Presentation Title: Improvement of Symptom Burden in Summit: Bezuclastinib in Adults with Nonadvanced Systemic Mastocytosis
Session Date and Time: February 28, 2026 – 9:45am – 10:45am ET
Poster Number: 523
Location: Convention Center, Ground Level, Hall A
Poster Presentation Title: Results from the Summit Pivotal Trial: Symptom improvement correlates with reductions in objective measures of disease in adults with nonadvanced systemic mastocytosis
Session Date and Time: February 28, 2026 – 9:45am – 10:45am ET
Poster Number: 532
Location: Convention Center, Ground Level, Hall A
Poster Presentation Title: Results in Subgroups with Unmet Need in the Summit Trial: Bezuclastinib in Adults with Nonadvanced Systemic Mastocytosis
Session Date and Time: February 28, 2026 – 9:45am – 10:45am ET
Poster Number: 521
Location: Convention Center, Ground Level, Hall A
About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2/3 inhibitor. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3K?, KRAS and JAK2. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X (formerly known as Twitter) and LinkedIn. Information that may be important to investors will be routinely posted on our website and X.
Contact:
Christi Waarich
Senior Director, Investor Relations
[email protected]
617-830-1653
FAQ**
How does Cogent Biosciences Inc Com COGT's focus on precision therapies differentiate it from other biotech firms in Waltham, MA, and Boulder, CO?
2. What are the potential market implications of the bezuclastinib results presented at the AAAAI Annual Meeting for Cogent Biosciences Inc Com COGT?
3. How might the Breakthrough Therapy Designation for bezuclastinib affect Cogent Biosciences Inc Com COGT's regulatory approval timeline and market strategy?
4. As Cogent Biosciences Inc Com COGT continues developing targeted therapies, what are the financial and operational impacts expected for its teams based in Waltham, MA, and Boulder, CO?
**MWN-AI FAQ is based on asking OpenAI questions about Cogent Biosciences Inc Com (NASDAQ: COGT).
NASDAQ: COGT
COGT Trading
-2.61% G/L:
$38.41 Last:
448,646 Volume:
$38.83 Open:
